# Renal Safety Evaluation After Dotarem®-Enhanced MRI

> **NCT00650845** · PHASE4 · COMPLETED · sponsor: **Guerbet** · enrollment: 135 (actual)

## Conditions studied

- Renal Insufficiency

## Interventions

- **DRUG:** Dotarem®-enhanced MRI
- **OTHER:** non-enhanced MRI

## Key facts

- **NCT ID:** NCT00650845
- **Lead sponsor:** Guerbet
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-01
- **Primary completion:** 2011-05
- **Final completion:** 2011-08
- **Target enrollment:** 135 (ACTUAL)
- **Last updated:** 2015-06-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00650845

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00650845, "Renal Safety Evaluation After Dotarem®-Enhanced MRI". Retrieved via AI Analytics 2026-07-15 from https://api.ai-analytics.org/clinical/NCT00650845. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*